Roche's Ventana PD-L1 (SP142) Receives FDA's Approval for Identifying Triple-Negative Breast Cancer (TNBC) as CDx
Shots:
- The approval is based on IMpassion130 study assessing Tecentriq + Abraxane vs PBO + Abraxane in patients with advanced or mTNBC with no prior therapy
- The Ventana PD-L1 (SP142) assay was used in Roche’s Tecentriq clinical trials to stratify patients and enhances the visual contrast of tumor-infiltrating immune cell staining
- The Ventana PD-L1 (SP142) assay is a companion diagnostic- performs specific staining of tumor cells with the use of OptiView DAB IHC detection kit with OptiView amplification kit and has received FDA’s Approval for UC & NSCLC with Tecentriq
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com